-
公开(公告)号：US11739101B2
公开(公告)日：2023-08-29
申请号：US17308879
申请日：2021-05-05
IPC分类号： C07D519/00 , C07D471/04 , C07D487/14 , C07D471/10 , A61P31/12 , A61P35/00 , A61P37/02 , A61P31/18 , A61P31/20 , A61K31/4545 , A61K47/55
CPC分类号： C07D519/00
摘要： The present disclosure provides bifunctional compounds as HPK1 degraders via ubiquitin proteosome pathway, and method for treating diseases modulated by HPK1.
-
公开(公告)号：US11203591B2
公开(公告)日：2021-12-21
申请号：US16669346
申请日：2019-10-30
发明人： Gayatri Balan , Mark J. Bartlett , Jayaraman Chandrasekhar , Julian A. Codelli , John H. Conway , Jennifer L. Cosman , Rao V. Kalla , Zachary A. Kasun , Musong Kim , Seung H. Lee , Jennifer R. Lo , Jennifer A. Loyer-Drew , Scott A. Mitchell , Thao D. Perry , Gary B. Phillips , Patrick J. Salvo , Sundaramoorthi Swaminathan , Joshua J. Van Veldhuizen , Suet C. Yeung , Jeff Zablocki
IPC分类号： C07D471/04 , A61K31/437 , C07D519/00
摘要： The present disclosure relates generally to certain 6-azabenzimidazole compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of diseases, disorders, or infections modifiable by hematopoietic progenitor kinase 1 (HPK1) inhibitors, such as HBV, HIV, cancer, and/or a hyper-proliferative disease.
-
公开(公告)号：US20210355140A1
公开(公告)日：2021-11-18
申请号：US17308879
申请日：2021-05-05
IPC分类号： C07D519/00
摘要： The present disclosure provides bifunctional compounds as HPK1 degraders via ubiquitin proteosome pathway, and method for treating diseases modulated by HPK1.
-
公开(公告)号：US20190388419A1
公开(公告)日：2019-12-26
申请号：US16413458
申请日：2019-05-15
发明人： Peter A. Blomgren , Kevin S. Currie , Jeffrey E. Kropf , Seung H. Lee , Jennifer R. Lo , Scott A. Mitchell , Aaron C. Schmitt , Sundaramoorthi Swaminathan , Jin-Ming Xiong , Jianjun Xu , Zhongdong Zhao
IPC分类号： A61K31/4985 , A61K31/5377 , A61K9/00 , C07D487/04
摘要： The present disclosure relates to compounds that are Syk inhibitors and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, the structure of the compounds is given by Formula I: wherein R1, R2, R3, and R4 are as described herein. The present disclosure further provides pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts or co-crystals thereof, and methods of using these compounds and compositions to treat conditions mediated by Syk.
-
![Substituted imidazo[1,2-a]pyrazines as Syk inhibitors](/abs-image/US/2019/07/09/US10342794B2/abs.jpg.150x150.jpg)
公开(公告)号：US10342794B2
公开(公告)日：2019-07-09
申请号：US15945685
申请日：2018-04-04
发明人： Peter A. Blomgren , Kevin S. Currie , Jeffrey E. Kropf , Seung H. Lee , Jennifer R. Lo , Scott A. Mitchell , Aaron C. Schmitt , Sundaramoorthi Swaminathan , Jin-Ming Xiong , Jianjun Xu , Zhongdong Zhao
IPC分类号： A61K31/4985 , C07D487/04 , A61K9/00 , A61K31/5377
摘要： The present disclosure relates to compounds that are Syk inhibitors and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, the structure of the compounds is given by Formula I: wherein R1, R2, R3, and R4 are as described herein. The present disclosure further provides pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts or co-crystals thereof, and methods of using these compounds and compositions to treat conditions mediated by Syk.
-
公开(公告)号：US20160096827A1
公开(公告)日：2016-04-07
申请号：US14863108
申请日：2015-09-23
发明人： Zhimin Du , Juan A. Guerrero , Joshua A. Kaplan , John E. Knox, JR. , Jennifer R. Lo , Scott A. Mitchell , Devan Naduthambi , Barton W. Phillips , Chandrasekar Venkataramani , Peiyuan Wang , William J. Watkins , Zhongdong Zhao
IPC分类号： C07D405/12 , C07D405/14 , A61K31/53 , C07D403/14 , C07D409/14 , A61K31/5383 , A61K31/5377 , C07D417/14 , C07D491/107 , C07D471/10 , C07D413/14 , C07D498/04 , A61K31/541 , C07D403/12
CPC分类号： C07D405/12 , A61K31/53 , A61K31/5377 , A61K31/5383 , A61K31/541 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/08 , C07D471/10 , C07D487/04 , C07D491/107 , C07D491/113 , C07D498/04
摘要： Compounds having the following formula (I) and methods of their use and preparation are disclosed:
-
公开(公告)号：US20230013585A1
公开(公告)日：2023-01-19
申请号：US17331900
申请日：2021-05-27
发明人： Gayatri Balan , Mark J. Bartlett , Jayaraman Chandrasekhar , Julian A. Codelli , John H. Conway , Jennifer L. Cosman , Rao V. Kalla , Musong Kim , Seung H. Lee , Jennifer R. Lo , Jennifer A. Loyer-Drew , Scott A. Mitchell , Thao D. Perry , Gary B. Phillips , Patrick J. Salvo , Joshua J. Van Veldhuizen , Suet C. Yeung , Jeff Zablocki
IPC分类号： A61K31/4545 , A61K31/444 , A61K31/5386 , C07D471/04 , C07D519/00
摘要： The present disclosure relates generally to certain 6-azabenzimidazole compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of diseases, disorders, or infections modifiable by hematopoietic progenitor kinase 1 (HPK1) inhibitors, such as HBV, HIV, cancer, and/or a hyper-proliferative disease.
-
公开(公告)号：US20220213091A1
公开(公告)日：2022-07-07
申请号：US17522628
申请日：2021-11-09
发明人： Gayatri Balan , Mark J. Bartlett , Jayaraman Chandrasekhar , Julian A. Codelli , John H. Conway , Jennifer L. Cosman , Rao V. Kalla , Zachary A. Kasun , Musong Kim , Seung H. Lee , Jennifer R. Lo , Jennifer A. Loyer-Drew , Scott A. Mitchell , Thao D. Perry , Gary B. Phillips , Patrick J. Salvo , Sundaramoorthi Swaminathan , Joshua J. Van Veldhuizen , Suet C. Yeung , Jeff Zablocki
IPC分类号： C07D471/04 , C07D519/00
摘要： The present disclosure relates generally to certain 6-azabenzimidazole compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of diseases, disorders, or infections modifiable by hematopoietic progenitor kinase 1 (HPK1) inhibitors, such as HBV, HIV, cancer, and/or a hyper-proliferative disease.
-
公开(公告)号：US20180280387A1
公开(公告)日：2018-10-04
申请号：US15907858
申请日：2018-02-28
发明人： Peter A. Blomgren , Astrid Clarke , Kevin S. Currie , Julie A. Di Paolo , Jeffrey E. Kropf , Seung H. Lee , Jennifer R. Lo , Scott A. Mitchell , Aaron C. Schmitt , Sundaramoorthi Swaminathan , Jin-Ming Xiong , Jianjun Xu , Zhongdong Zhao
IPC分类号： A61K31/4985 , A61K31/5377 , A61K31/519 , A61K31/475
摘要： The present disclosure relates to compounds that are Syk inhibitors and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, the structure of the compounds is given by Formula I: wherein R1, R2, R3, and R4 are as described herein. The present disclosure further provides pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by Syk. In certain embodiments, also disclosed are methods for treating a cancer in a subject (e.g., a human) in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt thereof, in combination with a vinca-alkaloid, or a pharmaceutically acceptable salt thereof.
-
公开(公告)号：US20240287061A1
公开(公告)日：2024-08-29
申请号：US18543272
申请日：2023-12-18
发明人： Gayatri Balan , Mark J. Bartlett , Jayaraman Chandrasekhar , Julian A. Codelli , John H. Conway , Jennifer L. Cosman Ellis , Rao V. Kalla , Zachary A. Kasun , Musong Kim , Seung H. Lee , Jennifer R. Lo , Jennifer A. Loyer-Drew , Scott A. Mitchell , Thao D. Perry , Gary B. Phillips , Patrick J. Salvo , Sundaramoorthi Swaminathan , Joshua J. Van Veldhuizen , Suet C. Yeung , Jeff Zablocki
IPC分类号： C07D471/04 , C07D519/00
CPC分类号： C07D471/04 , C07D519/00
摘要： The present disclosure relates generally to certain 6-azabenzimidazole compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of diseases, disorders, or infections modifiable by hematopoietic progenitor kinase 1 (HPK1) inhibitors, such as HBV, HIV, cancer, and/or a hyper-proliferative disease.
-
-
-
-
-
-
-
-
-
搜索结果
32 条记录 (耗时 0.039 秒)
